Marksans Pharma Limited (NSE: MARKSANS) reported financial results for Q2 and H1 FY27, marking a significant milestone with quarterly revenue crossing ₹900 crore for the first time. The company’s Q2FY27 EBITDA surged 48% to a record ₹214 crore, while H1FY27 PAT nearly doubled to ₹303 crore. Mark Saldanha, Founder, Chairman & Managing Director, highlighted the company’s strong performance, driven by broad-based growth across all regions.

Q2FY27 Highlights

In Q2FY27, Marksans Pharma’s operating revenue reached ₹940 crore, up 30.5% year-on-year (YoY). Adjusted for acquisition impact, revenue growth remained robust at 25%. EBITDA grew 48.3% to ₹214 crore, with margins expanding by 274 basis points to 22.8%. Notably, the UK & Europe market grew 64.9% to a record ₹405 crore, while the US & North America segment delivered its highest-ever quarter at ₹421 crore.

H1FY27 Performance

For H1FY27, revenue grew 32.9% to ₹1,781 crore. EBITDA rose 74.7% with margins up 574 basis points to 24.0%, and PAT nearly doubled to ₹303 crore. The company’s operating cash flow reached ₹322 crore, 4.3 times the previous year, and cash balances closed at ₹1,124 crore. Marksans Pharma’s trailing twelve-month return on capital employed (ROCE) improved to 24.7%.

Mark Saldanha emphasized the company’s expanding global footprint, robust product pipeline, and strong net-cash position. ‘We enter the next phase of our growth journey from a position of considerable strength,’ he said. ‘Our focus remains on sustaining profitable organic growth while selectively pursuing strategic acquisitions that strengthen our capabilities and market presence. We remain confident in our growth trajectory and committed to creating sustainable long-term shareholder value.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Marksans Pharma Limited

Marksans Pharma Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Marksans gains 16.4% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 16.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 1.7% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 16.7% and profits at 16.2%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Marksans Pharma Limited.

Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal second quarter ended September 30, 2026. The company reported total income of Rs 4,423 crore, up 1% year-on-year (YoY). The consolidated operating revenue increased 2% YoY to Rs 4,389 crore.

Financial Performance

Biopharma revenue increased 5% YoY to Rs 3,583 crore. Biosimilars revenue increased 3% YoY to Rs 2,809 crore, while generics revenue increased 10% YoY to Rs 774 crore. Services revenue increased 13% quarter-on-quarter (QoQ) to Rs 833 crore.

Leadership Comments

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, stated, ‘Biocon continued to achieve industry firsts in biosimilars, with our Pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway.’ Shreehas Tambe, CEO & Managing Director, Biocon Limited, added, ‘We are well positioned for growth in the second half of FY27, with the upcoming European launch of Pertuzumab and expanded insulin manufacturing capacity in Malaysia to support growing U.S. demand.’

As a result, Biocon Limited is confident in its long-term growth trajectory, driven by strategic milestones and continued investments in technology and innovation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) showcased robust growth in Q2 FY27, driven by strategic portfolio transformation and innovation. The company’s performance highlights the successful execution of its growth strategy, with key metrics reflecting significant advancements across various segments.

Key Financial Highlights

GLAXO’s revenue for Q2 FY27 surged by 21%, reaching ₹1,180 crore, while the first half of the fiscal year saw a 18% increase to ₹2,104 crore. The company’s EBITDA for Q2 FY27 stood at ₹400 crore, marking a 20% growth from the previous year. Notably, the PAT (profit after tax) before exceptional items grew by 33% to ₹335 crore, contributing to a margin improvement of 260 basis points to 29%.

Market Performance and Portfolio Strength

The pharmaceutical portfolio of GLAXO maintained its leadership, with a 25% share in the representative market. The General Medicines and Vaccines segments continued to outperform, with key brands like Augmentin, Calpol, and Neosporin showing significant unit growth rates. The Vaccines segment, particularly Shingrix, doubled in sales, driven by effective engagement with healthcare providers and organizations.

Future Outlook

Looking ahead, GLAXO remains committed to its growth trajectory through continued portfolio transformation and innovation. The company is set to launch new products in Oncology, Respiratory, and Adult Vaccines, aiming to further strengthen its market position and deliver sustained growth.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

GlaxoSmithKline posts a 4.5% three-month gain, but softens in the last few weeks. Industry-leading margins of 27.0% reflect exceptional pricing power and operational efficiency. The PEG of 2.11 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The stock gives back 10.2% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 5.7% and profits at 19.3%, with D/E of 0.01. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.11 premium is usually justified. Check Fundamentals of GlaxoSmithKline Pharmaceuticals Limited.